Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,738
datasets available to search
ShareScore release 0.9.0
Dataset results
2,738 results for “Multiple Sclerosis”
Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)
ClinicalTrials.gov study NCT04410991. IPD Sharing: YES. Countries: 28. Publications: 1.
Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis
ClinicalTrials.gov study NCT01357980. IPD Sharing: YES. Countries: 5. Publications: 1.
Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis
ClinicalTrials.gov study NCT00879658. IPD Sharing: UNDECIDED. Countries: 12. Publications: 2.
Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis
ClinicalTrials.gov study NCT02201108. IPD Sharing: YES. Countries: 22. Publications: 3.
A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis
ClinicalTrials.gov study NCT04486716. IPD Sharing: YES. Countries: 2. Publications: 1.
Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis
ClinicalTrials.gov study NCT04879628. IPD Sharing: YES. Countries: 10. Publications: 1.
Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1
ClinicalTrials.gov study NCT02660138. IPD Sharing: YES. Countries: 10. Publications: 1.
A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple Sclerosis
ClinicalTrials.gov study NCT05630547. IPD Sharing: YES. Countries: 10. Publications: 1.
Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)
ClinicalTrials.gov study NCT01665144. IPD Sharing: YES. Countries: 31. Publications: 7.
Gut microbiome of multiple sclerosis patients and paired household healthy controls reveal associations with disease risk and course
Open the record for dataset details and reuse information.
Data from: Multiple sclerosis-associated changes in the composition and immune functions of spore-forming bacteria
Open the record for dataset details and reuse information.
Gut Microbiota from Multiple Sclerosis patients triggers spontaneous autoimmune encephalomyelitis in mice --shotgun data--
Open the record for dataset details and reuse information.
Gut Microbiota from Multiple Sclerosis patients triggers spontaneous autoimmune encephalomyelitis in mice --16S data--
Open the record for dataset details and reuse information.
Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models
Open the record for dataset details and reuse information.
Dataset: The TCR repertoire reconstitution in multiple sclerosis: comparing one-shot and continuous immunosuppressive therapies
<p>This dataset, containing TCRbeta-chain data, is the basis for the following publication in Frontiers in Immunology: The TCR repertoire reconstitution in multiple sclerosis: comparing one-shot and continuous immunosuppressive therapies. The file key can be found in the file: file_key.xlsx. Relevant methodological details maybe found in the corresponding publication.</p>
Raw data related to: "Resiquimod-Mediated Activation of Plasmacytoid Dendritic Cells Is Amplified in Multiple Sclerosis"
<p><strong>Introduction</strong></p> <p>Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system. The cause of multiple sclerosis is unknown but there are several evidences that associate the genetic basis of the disease with environmental causes. An important association between viral infection and development of MS is clearly demonstrated. Viruses have a strong impact on innate immune cells. In particular, myeloid dendritic cells (mDCs) and plasmacytoid dendritic cells (pDCs), are able to respond to viruses and to activate the adaptive immune response.</p> <p><strong>Methods</strong></p> <p> In this study we mimic viral infection using synthetic single-strand RNA, Resiquimod, and we compared the response of both DC subsets derived from healthy donors and MS patients by characterizing the expression of costimulatory molecules on the DC surface.</p> <p><strong>Results</strong></p> <p>We found that pDCs from MS patients express higher levels of OX40-L. Moreover, we found that blood cells from MS patients and healthy donors upon Resiquimod-stimulation are enriched in a subpopulation of pDCs, characterized by a high amount of costimulatory molecules.</p> <p><strong>Conclusion</strong></p> <p>Overall, these results indicate that activation of pDCs is enhanced in MS, likely due to a latent viral infection, and that costimulatory molecules expressed on pDCs could mediate a protective response against the viral trigger of autoimmunity.</p>
Raw data to "Specialized pro-resolving lipid mediators are differentially altered in peripheral blood of patients with multiple sclerosis and attenuate monocyte and blood-brain barrier dysfunction"
<p>Background: Lack of resolution of inflammation may be considered a critical player for the onset and progression of multiple sclerosis. To demonstrate this we extracted lipids from plasma samples of healthy donors and MS patients and we quantified over 65 lipid mediators (LMs) through LC-MS-MS using signature diagnostic ions via multiple reaction monitoring.</p> <p>Results: Out of the 65 lipid mediators analyzed, only 42 were detected and out of those only 27 were finally revealed to show differences between healthy subjects and MS patients. These 27 LMs belonged to the arachidonic (AA), docosahexaenoic (DHA) or eicosapentaenoic (EPA) acid metabolomes and we could clusterize each form of MS into a specific profile by means of principal component analysis. Altogether, compared to healthy subjects, MS patients showed a strong production of several AA-derived eicosanoids (i.e. PGE2, PGD2 and PGF2a) (Fig.1D) and a little production of two DHA-derived pro-resolving mediators (SPMs), i.e. Protectin D1 (D1) and protectin DX (PDX) (Fig.1A). However, no production of DHA-derived resolvins and maresins (Fig. 1B) as well as EPA-derived resolvins (Fig.1 C) was observed.</p> <p>When stratifying MS patients according to disease form, both relapsing MS patients showed production of only two pro-resolving mediators (SPMs), i.e. Resolvin D1 (RvD1) and Protectin D1 (D1) compared to healthy subjects, whereas remitting MS patients showed a production of only few AA- and DHA-derived metabolic pathway markers and progressive MS patients a strong production of several eicosanoids as well as other metabolic pathway markers.</p> <p>Conclusions: These data suggest that along disease progression, there is a lack of production of anti-inflammatory and pro-resolving lipid mediators associated to a higher production of pro-inflammatory ones.</p>
Five-years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension
<p><b>Objective</b></p> <p>To assess over 3 years of follow-up, the effects of maintaining or switching to ocrelizumab (OCR) therapy on clinical and MRI outcomes and safety measures in the open-label extension (OLE) phase of the pooled OPERA studies in relapsing multiple sclerosis.</p> <p><b>Methods</b></p> <p>After 2 years of double-blind, controlled treatment, patients continued OCR (600 mg infusions every 24 weeks) or switched from interferon (IFN) β-1a (44 μg 3 times weekly) to OCR when entering the OLE phase (3 years). Adjusted annualized relapse rate, time to onset of 24-week confirmed disability progression/improvement (CDP/CDI), brain MRI activity (gadolinium-enhanced and new/enlarging T2 lesions), and percentage brain volume change were analyzed.</p> <p><b>Results</b></p> <p>Of patients entering the OLE phase, 88.6% completed Year 5. The cumulative proportion with 24-week CDP was lower in patients who initiated OCR earlier, vs patients initially receiving IFN β-1a (16.1% vs 21.3% at Year 5; <i>p</i>=0.014). Patients continuing OCR maintained, and those switching from IFN β-1a to OCR attained near complete and sustained suppression of new brain MRI lesion activity from Year 3 to 5. Over the OLE phase, patients continuing OCR exhibited less whole brain volume loss from double-blind study baseline vs those switching from IFN β-1a (–1.87% vs –2.15% at Year 5; <i>p</i><0.01). Adverse events were consistent with past reports and no new safety signals emerged with prolonged treatment.</p> <p><b>Conclusion</b></p> <p>Compared with patients switching from IFN β-1a, earlier and continuous OCR treatment up to 5 years provided sustained benefit on clinical and MRI measures of disease progression.</p>
Multiple Sclerosis: Cerebral Circulation Time is prolonged and not correlated with expanded disability status scale (EDSS). A study using digital subtracted angiography
<p>Dataset used to study the relationship between cerebral circulation time (CCT) and some clinical evidences, e.g. expand disability status scale (EDSS), disease duration, age at onset,... CCT was measured through the digital subtraction angiography (DSA) technique. </p> <p>Statistical Parametric Mapping software (SPM, Wellcome Department of Cognitive Neurology, Institute of Neurology, University College London; http://www.fil.ion.ucl.ac.uk/spm/) and ad-hoc scripts developed in the MATLAB scientific computing environment (http://www.mathworks.com, MathWorks, MA, USA) were applied to valuate the lesion volume and brain volume in MS patients.</p>
Raw data for SELDI-TOF high range from article: Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis
<p>Raw normalised data from SELDI-TOF at high range following Expression Difference Mapping (ProteinChip Data Manager. Bio-Rad). Columns contain sample name, sample group (corresponds to longitudinal measurements for each patients at 1,3,4 and 5), peak number (all peaks detected at high range at each time point), peak intensity and mass/charge ratio.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.